Despite early Medicaid expansion, decreased durable virologic suppression among publicly insured people with HIV in Washington, DC: a retrospective analysis

Table 2 IOM standards of care among treatment-naive DC Cohort participants, by insurance type and clinic type in Washington, DC, 2011–2015

	Total N(%)	Regular CD4 monitoring^a N(%)	P-value	Regular VL monitoring^b N(%)	P-value	Durable viral suppression^c N(%)	P-value
Insurance
Public	115(62.2)	91(79.1)	0.057	96(83.5)	0.042	61(53.1)	0.030
Private	70(37.8)	46(65.7)	0.057	49(70.0)	0.042	49(70.0)	0.030
Site
Hospital-based	95(51.4)	73(76.8)	0.405	74(77.9)	0.870	51(53.7)	0.134
Community-based	90(48.7)	64(71.1)	0.405	71(78.9)	0.870	59(65.6)	0.134
*SiteInsurance**
Hospital-based/ Public	42(44.2)	34(80.9)	0.468	36(85.7)	0.137	16(38.1)	0.008
Hospital-based/ Private	53(55.8)	39(73.6)	0.468	38(71.7)	0.137	35(66.1)	0.008
Community-based/ Public	73(81.1)	57(78.1)	0.006	60(82.2)	0.183	45(61.6)	0.157
Community-based/ Private	17(18.9)	7(41.2)	0.006	11(64.7)	0.183	14(82.4)	0.157

Note: ART status was determined at enrollment date. P-values based on X² statistics and cross checked with Fisher’s exact test
^a Regular CD4 monitoring is defined as at least two CD4 lab measures 30 days apart in the 12 months following the index date
^b Regular VL monitoring is defined as at least two CD4 lab measures 30 days apart in the 12 months following the index date
^c Durable viral suppression is defined as last viral load < 50 copies/ML in the 12 months following the index date. Index date was defined as either the date of ART initiation or the date of study enrollment, whichever was later

ISSN: 1471-2458